Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 93Neoplasm Metastasis 6Prostatic Neoplasms, Castration-Resistant 3Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2Neoplasms 2Genital Diseases, Male 2Urogenital Neoplasms 1Stage II Prostate Adenocarcinoma 1Small Cell Lung Carcinoma 1Sleep Initiation and Maintenance Disorders 1Salivary Gland Neoplasms 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Patient Preference 1Non-metastatic Prostate Cancer 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Low Risk Prostate Cancer 1High-Risk and Oligometastatic Prostate Cancer 1

Interventions

padeliporfin 4darolutamide 2apalutamide 2Abiraterone Acetate 2palladium-bacteriopheophorbide 1onapristone 1niraparib 1ixabepilone 1gedatolisib 1gallium 68 PSMA-11 1enzalutamide 1abiraterone 1Therapeutics 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Imatinib Mesylate 1EPI-506 1Docetaxel 1BAY 86-7548 1Androgen Antagonists 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Genital Diseases, Male × apalutamide × Clear all
NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

NCT02578797 2023-11-09

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Aragon Pharmaceuticals, Inc.

Phase 1 Completed
45 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡